The 301 study compared treatment with Feraheme to treatment with placebo. The study was robust, enrolling 808 at 136 sites in the United States, Canada, India, Latvia, Hungary, and Poland. The patients enrolled in this study, as I mentioned, had a history of unsatisfactory response to oral iron or could not otherwise tolerate oral iron, and therefore they never achieved the desired clinical benefit from oral iron treatment. As in IDA-302, the patients enrolled in this study had iron deficiency anemia associated with various conditions including abnormal uterine bleeding, cancer, gastrointestinal disorders or other causes.Patients in this study were randomized 3:1 to receive a 1.0 gram intravenous course of Feraheme or placebo with 608 patients randomized through the Feraheme treatment arm and 200 patients randomized through the placebo treatment arm. This study was designed to demonstrate superiority on efficacy. The demographics and baseline parameters were found to be well balanced between the two treatment groups with a mean baseline hemoglobin level of 8.9 g/dL in the Feraheme arm and 8.8 g/dL in the placebo arm.
AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.